

## Conference Highlights featuring ACTC Collaborators

This itinerary lists some of the main sessions being presented at CTAD (keynotes and symposiums), as well as those where ACTC members are either presenting or have co-authored the presentation. We hope this highlights and provides insight into some of the work being done by ACTC members and collaborators.

*Sessions are listed in Central European Time.*

*Schedule is current at the time of posting. Titles are listed as submitted.*

### Sessions featuring ACTC Collaborators as Presenters / Co-Authors

Date and Time	Session Information
Tuesday, Oct 29 4:00pm	<b>Opening Ceremony and CTAD Lifetime Achievement Award</b> Presented to Lars Lannfelt, MD, PhD
Tuesday, Oct 29 4:30pm	<b>Keynote 1 – Lecanemab: from a mutation to a treatment for Alzheimer’s disease</b> Lars Lannfelt, <i>Uppsala University</i>
Tuesday, Oct 29 6:10pm	<b>Late breaking Symposium 1 – The AHEAD Study: Design and Results of a Novel Screening Process for a Preclinical AD Trial</b> Rema Raman, <i>Alzheimer’s Therapeutic Research Institute, University of Southern California</i>  <b>Presentation 1: The AHEAD A3-45 Study: Adaptation to Challenges</b> Paul Aisen, <i>Alzheimer’s Therapeutic Research Institute, University of Southern California</i>  <b>Presentation 2: Screening Plasma Biomarkers, Amyloid and Tau PET Imaging in the AHEAD 3-45 Study</b> Reisa Sperling, <i>Brigham and Women’s Hospital, Harvard Medical School, and Massachusetts General Hospital</i>  <b>Presentation 3: Racial and Ethnic Differences in Plasma P-tau217 Biomarker Eligibility Rates in a Preclinical AD Trial</b> Doris Molina Henry, <i>Alzheimer’s Therapeutic Research Institute, University of Southern California</i>
Wednesday, Oct 30 8:30am	<b>LB1 – Donanemab: Appropriate Use Recommendations</b> Gil Rabinovici, Stephen Salloway, Suzzane Schindler, Paul Aisen, Liana Apostolova, Alireza Atri, Steven Greenberg, Suzanne Hendrix, Ron Petersen, Michael Weiner, Dennis Selkoe, Jeffrey Cummings
Wednesday, Oct 30 9:15am	<b>Keynote 2 – Next Generation of Clinical Trials for Alzheimer’s Disease and Related Disorders</b> Catherine Mummery, <i>Dementia Research Center, University College of London</i>
Wednesday, Oct 30 9:40am	<b>Symposium 1 – Does the Current Evidence Base Support Continued Dosing with Lecanemab for Early Alzheimer’s Disease?</b> Christopher van Dyck, <i>Yale University</i>  <b>Presentation 1: Mechanistic Rationale for Continued Lecanemab Dosing</b> Michael Irizarry, <i>Eisai Inc</i>

## Conference Highlights featuring ACTC Collaborators

	<p><b>Presentation 2: Pharmacologic Support for a Maintenance Dosing Regimen with Lecanemab: An Update on the Latest Clinical Pharmacology Data and Modeling</b> Larisa Reyderman, <i>Eisai Inc</i></p> <p><b>Presentation 3: Evidence for a Continued Benefit for Long-Term Lecanemab Treatment: A Benefit/Risk Update from Long-Term Efficacy, Safety and Biomarker Data</b> Christopher van Dyck, <i>Yale University</i></p>
Wednesday, Oct 30 1:45pm	<p><b>ROUNDTABLE</b> <b>Advancing Combination Therapy: Discussion on key Considerations, Perspectives, and Promising Avenues for the Future of Alzheimer’s Treatments</b> Howard Fillit, Jeffrey Cummings, Suzanne Hendrix, Jin Zhou, Mark Mintun</p>
Wednesday, Oct 30 3:30pm	<p><b>Late Breaking Symposium 2 – One-Year Experience on the Use of Lecanemab in Clinical Practice</b> Lefkos Middleton, <i>ICL – London</i>, Bruno Vellas, <i>IHU HealthAge – Toulouse</i></p> <p><b>Presentation 1: Lecanemab Treatment in Real World Settings in the United States</b> Marwan Sabbagh, <i>Barrow Neurological Institute</i></p>
Thursday, Oct 31 8:45am	<p><b>LB8 – Bridging the gap: parahippocampal tau-PET improves detection of the transition from age-related tauopathy to Alzheimer’s disease</b> Emma Thibault, Michelle Farrell, Jessie Fanglu Fu, Justin Sanchez, Brian Healy, Bernard Hanseeuw, Heidi Jacobs, Julie Price, J. Alex Becker, Reisa Sperling, Keith Johnson</p>
Thursday, Oct 31 9:00am	<p><b>LB10 – Discrepancies between CSF and PET determinations of elevated brain amyloid and their prognostic significance</b> David Knopman, Stephen Weigand, Heather Wiste, Jonathan Graff-Radford, Neill Graff-Radford, Ronald Petersen, Clifford Jack, Mary Machulda, Julie Fields, Vijay Ramanan, Hugo Botha, Stuart Mccarter, David Jones, Bryan Neth, Gregory Day, Alicia Algeciras-Schimmich, Joshua Bornhorst, Val Lowe, Derek Johnson, Bradley Boeve</p>
Thursday, Oct 31 9:45am	<p><b>Keynote 3 – Interim observations on developing drugs for people living with AD: What do they want, what can they have, and how can we do better?</b> Rachelle Doody</p>
Thursday, Oct 31 2:00pm	<p><b>Keynote 4 – Fluid biomarkers in research, clinical trials, and clinical practice</b> Suzanne Schindler, <i>Washington University in St. Louis</i></p>
Thursday, Oct 31 3:10pm	<p><b>LB16 – The anatomy of tau PET associations with biomarkers and cognitive decline in the A4 study</b> Justin Sanchez, Michael Properzi, Aaron Schultz, Emma Thibault, Muichelle Farrell, Alex Becker, Bernard Hanseeuw, Paul Aisen, Rema Raman, Michael Donohue, Reisa Sperling, Keith Johnson</p>
Thursday, Oct 31 5:10pm	<p><b>Late Breaking Symposium 3 – Results from TOGETHER, a double-blind, placebo-controlled Phase 11 study evaluating efficacy, safety and tolerability of bepranemab in prodromal-mild AD</b> Randall Bateman, <i>Washington University in St. Louis</i></p>

## Conference Highlights featuring ACTC Collaborators

<p>Friday, Nov 1 9:00am</p>	<p><b>LB23 – Effects of initial medial temporal lobe tauopathy and amyloid-beta on the timeline to caTAUstrophe</b> Michelle Farrell, Emma Thibault, Grace Del Carmen Montenegro, Jessie Fanglu Fu, Julie Price, Bernard Hanseeuw, John Sims, Roy Yaari, Sergey Shcherbinin, Karen Holdridge, Rema Raman, Michael Donohue, Paul Aisen, Reisa Sperling, Keith Johnson</p>
<p>Friday, Nov 1 9:30am</p>	<p><b>OC31 – The Alzheimer’s Tau Platform (ATP) and Progressive Supranuclear Palsy Trial Platform (PTP): a combination amyloid and tau therapy for early AD and a tau monotherapy trial for mild-moderate PSP</b> Adam Boxer, Keith Johnson, Irene Litvan, Julio Rojas, Anne-Marie Wills, Reisa Sperling, Paul Aisen, Ron Petersen, Randall Bateman, Chihiro Sato, Michael Donohue, Rema Raman, Eden Barragan</p>
<p>Friday, Nov 1 11:15am</p>	<p><b>LB26 – Sex Moderates Relationships Between P-Tau217 and Longitudinal Tau-PET: Findings from the A4 and LEARN studies</b> Gillian Coughlan, Hannah Klinger, Mabel Seto, Colin Birkenbihl, Michelle Farrell, Robert Rissman, Michael Properzi, Diana Townsend, Hyun-Sik Yang, Keith Johnson, Oliver Langford, Michael Donohue, Reisa Sperling, Rachel Buckley</p>
<p>Friday, Nov 1 1:30pm</p>	<p><b>Late Breaking Symposium 4 – Cannabinoid based medications for neuropsychiatric symptoms in Alzheimer’s dementia</b> Krista Lanctot</p> <p><b>Presentation 4: The Use of THC and CBD in the Treatment of Agitated Persons Living with Dementia as the End of Life</b> <i>Olga-Brawman-Mintzer, Ralph H. Johnson VA Healthcare System and Medical University of South Carolina, Charleston</i></p>
<p>Friday, Nov 1 2:25pm</p>	<p><b>OC36 – Artificial Intelligence-enabled Safety Monitoring in Alzheimer’s Disease Clinical Trials</b> Gustavo Jimenez-Maggiola, Michael Donohue, Michael Rafii, Rema Raman, Paul Aisen</p>
<p>Friday, Nov 1 3:55pm</p>	<p><b>LB30 – Amyloid modifies the association between late-life BMI and longitudinal cognition in cognitively unimpaired individuals</b> Wai-Ying Wendy Yau, Rema Raman, Shunran Wang, Neelum Aggarwal, Adam Brickman, Jasmeeer Chhatwal, Petrice Cogswell, Jonathan Graff-Radford, Jay Pillai, Prashanthi Vemuri, Michael Rafii, Paul Aisen, Reisa Sperling, The A4 and LEARN Study Teams</p>